Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Lung Cancer 2026

View at publisher
Authors: Isamu Okamoto, Byoung Chul Cho, Sarah B. Goldberg, Jonathan W. Goldman, Adrianus J. de Langen, Zofia Piotrowska, Jonathan W. Riess, Helena A. Yu, MRosario Garcia Campelo, Jeremy Cetnar, Yu Jung Kim, Silvia Novello
+6 more Yoshimasa Shiraishi, Helen Ambrose, Paul. E. Smith, Kwan Ho Tang, Jonathan M. Lehman, Xiuning Le
DOI: 10.1016/j.lungcan.2026.109501
Cited by: 3
References: 40

Fields of Study & Subjects

Lung Cancer Research Studies Lung Cancer Treatments and Mutations Advanced Breast Cancer Therapies

Publication details

Journal / source
Lung Cancer
Publisher
Elsevier BV
Volume
218
Pages
109501–109501
Publication date
18 June 2026
Language
EN